It's been a difficult road for Aastrom Biosciences (ASTM) over the past two years, but management remains committed to its platform and sees potential with ixmyelocel-T in dialated cardiomyopathy (DCM). We will find out if the strategy pays off in 2015.
Enrollment in the Phase 2 ixCELL-DCM study, initiated in April 2013, continues on plan. The company had previously generated strong proof-of-concept in DCM. A twelve month follow-up analysis from the company's phase 2a Catheter-DCM study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) in May 2012. Slides from this presentation can be found via this link. This was a 22 patient study designed to evaluate the safety and efficacy of...
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: